Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010

Nava, Francesca; Tramacere, Irene; Fittipaldo, Veronica Andrea; Bruzzone, Maria Grazia; DiMeco, Francesco; Fariselli, Laura; Finocchiaro, Gaetano; Pollo, Bianca; Salmaggi, Andrea; Silvani, Antonio; Farinotti, Mariangela; Filippini, Graziella

doi:10.1093/neuonc/not316

Cited by 66 publications

(54 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We compared our data with the analysis of “Cohort II” from a retrospective analysis of therapy response performed by Nava et al [29]. Cohort II was composed of 746 patients with histologically confirmed primary GB who were diagnosed and treated with the Stupp protocol [1] as a firstline treatment, and new standard protocols for second-line chemotherapy and radiosurgery after tumor recurrence.…”

Section: Discussionmentioning

confidence: 99%

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients

et al. 2016

View full text Add to dashboard Cite

The purpose of this pilot study was to determine whether blood-borne microvesicles from newly diagnosed glioblastoma patients could be used as biomarkers. We collected 2.8 mL blood from 16 post-operative patients at the time that they were being simulated for chemoradiation therapy (radiation with concurrent temozolomide). Two additional samples were collected during chemoradiation therapy and a final sample was collected at the end of chemoradiation therapy. Patients continued with the therapy suggested by their physicians, based on tumor conference consensus and were followed for recurrence and overall survival. Microvesicles were isolated using serial centrifugation and stained for surface markers (Annexin V for phosphotidyl serine, CD41 for platelets, anti-EGFR for tumor cells, and CD235 for red blood cells). Flow cytometry analysis was performed. Our findings provide initial evidence that increases in Annexin V positive microvesicle levels during chemoradiation therapy are associated with earlier recurrence and shorter overall survival in newly diagnosed glioblastoma patients. The effect is dramatic, with over a four-fold increase in the hazard ratio for an individual at the 75th versus the 25th percentile. Moreover the pattern of Annexin V positive microvesicles remain significant after adjustment for confounding clinical variables that have previously been shown to be prognostic for recurrence and survival. Inclusion of neutrophil levels at the start of chemoradiation therapy in the model yielded the largest attenuation of the observed association. Further studies will be needed to verify and further investigate the association between these two entities.

show abstract

Section: Discussionmentioning

confidence: 99%

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A prospective registry study of 764 patients with glioblastoma analyzed over a 7-year period (2004)(2005)(2006)(2007)(2008)(2009)(2010) with one third of patients reoperated at recurrence did not suggest a benefit of repeat surgery (HR 1.02), however, no detailed patient stratification for prognostic variables was available [28]. Similarly, in a meta-analysis of 8 prospective phase I and II trials comprising 300 patients with recurrent glioblastoma repeat surgery was not an independent predictor for PFS and OS [29].…”

Section: Surgery At Recurrencementioning

confidence: 99%

Therapeutic options in recurrent glioblastoma—An update

Seystahl

Wick

Weller

2016

Critical Reviews in Oncology/Hematology

171

130

View full text Add to dashboard Cite

show abstract

“…The current options include further surgery, second line chemotherapy and stereotactic radiosurgery [24]. Therefore, there is a clear need to identify novel therapeutic approaches to improve outcomes [25].…”

Section: Discussionmentioning

confidence: 99%

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

Whittle

Lickliter

Gan

et al. 2015

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010

Cited by 66 publications

References 45 publications

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients

Therapeutic options in recurrent glioblastoma—An update

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

Contact Info

Product

Resources

About